Telmisartan and moksonidin’s opportunities in treatment of arterial hypertension

Gaponova N.I.; Kositsyna I.V.; Abdrakhmanov V.R.; Golubev A.V.; Galaktionov P.S.

doi:https://doi.org/10.17116/kardio202013021120

Gaponova N.I.

Moskovskiĭ gosudarstvennyĭ mediko-stomatologicheskiĭ universitet

Kositsyna I.V.

A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of Russia, Moscow, Russia

Abdrakhmanov V.R.

A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of Russia, Moscow, Russia

Golubev A.V.

Krasnoiarskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. prof. V.F. Voĭno-Iasenetskogo

Galaktionov P.S.

A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of Russia, Moscow, Russia

Telmisartan and moksonidin’s opportunities in treatment of arterial hypertension

Authors:

Gaponova N.I., Kositsyna I.V., Abdrakhmanov V.R., Golubev A.V., Galaktionov P.S.

More about the authors

Journal: Russian Journal of Cardiology and Cardiovascular Surgery. 2020;13(2): 120‑126

DOI: 10.17116/kardio202013021120

Read: 25707 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Gaponova NI, Kositsyna IV, Abdrakhmanov VR, Golubev AV, Galaktionov PS. Telmisartan and moksonidin’s opportunities in treatment of arterial hypertension. Russian Journal of Cardiology and Cardiovascular Surgery. 2020;13(2):120‑126. (In Russ.)
https://doi.org/10.17116/kardio202013021120

Подписка 2026 Кардиология и сердечно-сосудистая хирургия (Russian Journal of Cardiology and Cardiovascular Surgery)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Angiotensin model as a new approach to study of mesenchymal stem cell senescence. Russian Cardiology Bulletin. 2025;(2):20-26

Influence of physical therapy on intestinal microbiota, blood pressure control and systemic inflammation level: a randomized controlled study of 84 patients with arterial hypertension. Problems of Balneology, Physiotherapy and Exercise Therapy. 2025;(2):11-20

Development of conditions for determination of imidazole derivatives in the blood using chromatography-mass spectrometry. Forensic Medical Expertise. 2025;(3):32-37

Risk of ischemic heart diseases adverse outcomes in the working age men and women taking part in the prospective epidemiological surveillance. Russian Journal of Preventive Medicine. 2025;(6):60-66

Cardiovascular risk in patients with ulcerative colitis and arterial hypertension: what needs to be considered?. Russian Journal of Preventive Medicine. 2025;(6):106-113

Postoperative pain as a cause of hypertension progression in women with preeclampsia after cesarean section. Russian Journal of Pain. 2025;(2):83-90

Association of the ischemic heart disease with blood pressure, age and work experience in men with shift work in the Far North. Russian Journal of Preventive Medicine. 2025;(8):34-40

Assessment of biomarker levels in patients with STEMI, depending on the presence of cardiovascular events. Russian Journal of Preventive Medicine. 2025;(8):96-101

Visceral obesity is a reversible factor in pathogenesis of major cardiovascular diseases. Russian Cardiology Bulletin. 2025;(3):11-16

Features of the interpretation of bodily sensations by patients with arterial hypertension. Russian Journal of Preventive Medicine. 2025;(10):82-87

Abstract:

Arterial hypertension is an independent risk factor for the development of adverse cardiovascular events, disability and mortality. Adequate blood pressure control is a pressing issue that is now receiving increasing attention. The article provides an overview of clinical studies of the angiotensin II receptor blocker telmisartan, a drug that has shown efficacy for the treatment of arterial hypertension both in monotherapy and in combination with other classes of antihypertensive drugs. Data of clinical studies on positive influence of telmisartan on the course of diabetes mellitus, frequency of development of repeated strokes, remodeling of heart chambers are presented. The article also considers possibilities of using imidazoline receptor antagonist moxonidine in therapy of arterial hypertension in special cases.

Keywords:

arterial hypertension

cardiovascular events

telmisartan

moxonidine

Authors:

Gaponova N.I.

Moskovskiĭ gosudarstvennyĭ mediko-stomatologicheskiĭ universitet

Kositsyna I.V.

A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of Russia, Moscow, Russia

Abdrakhmanov V.R.

A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of Russia, Moscow, Russia

Golubev A.V.

Krasnoiarskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. prof. V.F. Voĭno-Iasenetskogo

Galaktionov P.S.

A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of Russia, Moscow, Russia

Close metadata

References:

Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, Alexander L, Estep K, Abate KH, Akinyemiju TF, Ali R, Alvis-Guzman N, Azzopardi P, Banerjee A, Bärnighausen T, Basu A, Bekele T, Bennett DA, Biadgilign S, Catalá-López F, Feigin VL, Fernandes JC, Fischer F, Gebru AA, Gona P, Gupta R, Hankey GJ, Jonas JB, Judd SE, Khang Y-H, Khosravi A, Kim YJ, Kimokoti RW, Kokubo Y, Kolte D, Lopez A, Lotufo PA, Malekzadeh R, Melaku YA, Mensah GA, Misganaw A, Mokdad AH, Moran AE, Nawaz H, Neal B, Ngalesoni FN, Ohkubo T, Pourmalek F, Rafay A, Kumar Rai R, Rojas-Rueda D, Sampson UK, Santos IS, Sawhney M, Schutte AE, Sepanlou SG, Shifa GT, Shiue I, Tedla BA, Thrift AG, Tonelli M, Truelsen T, Tsilimparis N, Ukwaja KN, Uthman OA, Vasankari T, Venketasubramanian N, Vlassov VV, Vos T, Westerman R, Yan LL, Yano Y, Yonemoto N, El Sayed Zaki M, Murray CJL. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990—2015. . 2017;317:165-182.
Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. . 2016;387:957-967.
Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. . 2014;32:2285-2295.
Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). . 2018 Sept;39(33);3021-3104.
Chazova IE, Zhernakova YV. on behalf of the experts. Clinical guidelines. Diagnostic and treatment of arterial hypertension. . 2019;16(1):6-31.
Reboldi G, Angeli F, Cavallini C, Gentile G, Mancia G, Verdecchia P. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. . 2008;26:1282-1289.
Volpe M, Mancia G, Trimarco B. Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds. . 2005;23:2113-2118.
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 Evidence-based guideline for the management of high blood pressure in adults. Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). . 2014;311(5):507-520.
Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, Blumenthal RS, Cannon CP, de Lemos JA, Elliott WJ, Findeiss L, Gersh BJ, Gore JM, Levy D, Long JB, O’Connor CM, O’Gara PT, Ogedegbe O, Oparil S, White WB. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American He art Association, American College of Cardiology, and American Society of Hypertension. . 2015;9(6):453-498.
Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). . 2013;31:1281-1357.
Aoyama T, Minatoguchi S. The effect of ARB on prevention of atherosclerosis. . 2011;69:92-99.
Li YR. Hoboken: John Wiley & Sons; 2015.
Negro R. Endothelial effects of antihypertensive treatment: focus on irbesartan. . 2008;4:89-101. https://doi.org/10.2147/vhrm.2008.04.01.89.
Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials. . 2017;35:2150-2160.
Burnier M. Telmisartan: a different angiotensin II receptor blocker protecting a different population? . 2009;37(6):1662-1679.
Kakuta H, Sudoh K, Sasamata M, Yamagishi S. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. . 2005;25(1):41-46.
Wienen W, Entzeroth M, Meel JA, Stangier J, Busch U, Ebner T, Schmid J, Lehmann H, Matzek KM, Kempthorne-Rawson J, Gladigau V, Hauel N. A Review on Telmisartan: A Novel, Long-Acting Angiotensin II-Receptor Antagonist. . 2000;18(2):127-154.
Instructions for use of the medicinal product for medical use Telmisartan. Accessed August 24, 2017. (In Russ.) Available at:
ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumachr H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. . 2008;358:1547-1559.
Böhm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Mann JFE, Mancia G, Redon J, Schmieder RE, Sliwa K, Weber MA, Williams B, Yusuf S. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. . 2017 June 3;389(10085):2226-2237.
Verdecchia P, Sleight P, Mancia G, Fagard R, Trimarco B, Schmieder RE, Kim JH, Jennings G, Jansky P, Chen JH, Liu L, Gao P, Probstfield J, Teo K, Yusuf S. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. . 2009;120:1380-1389.
Yusuf’s S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW. Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events. . 359(12):1225-1237.
Galzerano D, Di Michele S, Paolisso G, Tuccillo B, Lama D, Carbotta S, Cittadini A, Tedesco MA, Gaudio C. A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrial fibrillation recurrence in hypertensive patients. . 2012 Apr;13(4).
Fogari R, Mugellini A, Zoppi A, Preti P, Destro M, Lazzari P, Derosa G. Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation. . 2012 Mar;17(1):34-43.
Takagi H, Niwa M, Mizuno Y, Goto SN, Umemoto T. Telmisartan as a metabolic sartan: the first meta-analysis of randomized controlled trials in metabolic syndrome. . 2013;7(3):229-235.
Mori Y, Tanaka T, Matsuura K, Yokoyama J, Utsunomiya K. Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB Trial of Hypertension in Obese Patients with Hyperinsulinemia Assessed by Oral Glucose Tolerance Test (ATHLETE). . 2011;28(8):698-706.
Mensah GA, Bakris G. Treatment and control of high blood pressure in adults. . 2010;28:609-622.
McInnes GT. Antihypertensive drugs in combination: additive or greater than additive? . 2007;21(12):914-916.
Quan A, Chavanu K, Merkel J. A review of the efficacy of fixed-dose combinations olmesartan medoxomil/hydrochlorothiazide and amlodipine besylate/benazepril in factorial design studies. . 2006;6(2):103-113.
Neldam S, Edwards C, Lang M, Jones R. Long-term tolerability and efficacy of single-pill combinations of telmisartan 40—80 mg plus amlodipine 5 or 10 mg in patients whose blood pressure was not initially controlled by amlodipine 5—10 mg: Open-label, long-term follow-ups of the TEAMSTA-5 and TEAMSTA-10 studies. . 2012;73:65-84.
Neutel JM, Littlejohn TW, Chrysant SG, Singh A. Telmisartan/Hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild-to-moderate hypertension. . 2005;28(7):555-563.
Kobalava ZhD, Konradi AO, Nedogoda SV, Arutyunov GP, Baranova EI, Barbarash OL, Villevalde SV, Galyavich AS, Glezer MG, Drapkina OM, Kotovskaya YuV, Libis RA, Lopatin YuM, Nedoshivin AO, Ostroumova OD, Ratova LG, Tkacheva ON, Chazova IE, Chesnikova AI, Chumakova GA. Russian Society of Cardiology position paper on 2018 Guidelines of the European Society of Cardiology / European Society of Arterial Hypertension for the management of arterial hypertension. . 2018;(12):131-142. (In Russ.)
Prikaz Minzdrava Rossii ot 22 yanvarya 2016 g. No. 36N «Ob utverzhdenii trebovanij k komplektatsii lekarstvennymi preparatami i meditsinskimi izdeliyami ukladok i naborov dlya okazaniya skoroj meditsinskoj pomoshchi». Prikaz Minzdrava Rossii ot 5 iyulya 2016 g. No. 470N «Ob utverzhdenii standarta skoroj meditsinskoj pomoshchi pri gipertenzii». (In Russ.)
Gaponova NI, Abdrakhmanov VR. Place of original moxonidine in arterial hypertension treatment. . 2017;11(89):51-58.
Gaponova NI, Tereschenko SN, Abdrakhmanov VR. Evaluation of antihypertensive of efficacy and safety of moxonidine for treatment of uncomplicated hypertensive crisis. . 2013;10(1):40-47.
Schwarz W, Kandziora J. Long-term experiences with moxonidine, a new antihypertensive agent. Fortschr. Med.1990;32:616-620.
Mitrovic V, Patyna W, Hüting J, Schlepper M. Hemodynamic and neurohumoral effects of moxonidine in patients with essential hypertension. Cardiovasc. . 1991;6:967-972.
Fenton C, Keating GM, Lyseng-Williamson KA. Moxonidine: a review of its use in essential hypertension. . 2006;66:477-496.
Derosa G, Cicero AF, D’Angelo, Fogari E, Salvadeo S, Gravina A, Ferrari I, Fassi R, Fogari R. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial. . 2007;29:602-610.